Secukinumab in multi-failure psoriatic patients: the last hope?

Secukinumab in multi-failure psoriatic patients: the last hope?

J Dermatolog Treat. 2018 Jan 15;:1-9

Authors: Magnano M, Loi C, Patrizi A, Sgubbi P, Balestri R, Rech G, Tasin L, Girardelli CR, Conti A, Odorici G, Campanati A, Offidani AM, Bardazzi F

Abstract
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent, and, in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also those agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, recently approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

PMID: 29334270 [PubMed - as supplied by publisher]

http://ift.tt/2mAQHI1